Creative Planning
FDMT icon

Creative Planning’s 4D Molecular Therapeutics FDMT Stock Holding History

Creative Planning’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Sell
28,321
-839
-3% -$8.17K ﹤0.01% 3405
2026
Q1 		$271K Sell
29,160
-15,035
-34% -$131K ﹤0.01% 3493
2025
Q4 		$331K Buy
44,195
+6,485
+17% +$65.8K ﹤0.01% 3175
2025
Q3 		$328K Buy
+37,710
New +$225K ﹤0.01% 3073
2025
Q1 		– Sell
-517
Closed -$2.88K – 3552
2024
Q4 		$2.88K Buy
+517
New +$4.06K ﹤0.01% 3440

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Creative Planning's FDMT Position: Q2 2026 in Review

Creative Planning reduced its 4D Molecular Therapeutics (FDMT) stake by 2.9% in Q2 2026, selling an estimated $8.17K and leaving 28,321 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Creative Planning first reported a position in FDMT in Q4 2024 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Creative Planning held 28,321 shares of 4D Molecular Therapeutics worth $377K as of Q2 2026.
  • Creative Planning sold 839 4D Molecular Therapeutics shares in Q2 2026, an estimated $8.17K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3405 holding.
  • Creative Planning first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.